QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
QQQ   314.01 (+0.69%)
Log in
CNSX:TRYP

Tryp Therapeutics Stock Forecast, Price & News

Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Tryp Therapeutics Inc., a pharmaceutical company, focuses on developing compounds with known activity and/or safety profiles for the treatment of rare or orphan diseases and other diseases with high unmet medical needs. The company's lead development program is psilocybin-for-neuropsychiatry, or PFN, which is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. Its program candidates include TRP-8802 that has indication for fibromyalgia, a condition characterized by pain that is chronic and widespread; and TRP-1001, an oral formulation of razoxane evaluating for the treatment of soft tissue sarcoma. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was founded in 2019 and is headquartered in Kelowna, Canada.

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange CNSX
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolCNSX:TRYP
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.tryptherapeutics.com
Phone833 811 8797
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive TRYP News and Ratings via Email

Sign-up to receive the latest news and ratings for TRYP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tryp Therapeutics (CNSX:TRYP) Frequently Asked Questions

What stocks does MarketBeat like better than Tryp Therapeutics?

Wall Street analysts have given Tryp Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tryp Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Tryp Therapeutics' key executives?

Tryp Therapeutics' management team includes the following people:
  • Dr. James S. Kuo M.B.A., M.D., Chief Exec. Officer and Director (Age 55)
  • Dr. James P. Gilligan, Pres & Chief Science Officer (Age 68)

What is Tryp Therapeutics' stock symbol?

Tryp Therapeutics trades on the CNSX under the ticker symbol "TRYP."

How do I buy shares of Tryp Therapeutics?

Shares of TRYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tryp Therapeutics' official website?

The official website for Tryp Therapeutics is www.tryptherapeutics.com.

How can I contact Tryp Therapeutics?

The company can be reached via phone at 833 811 8797.

This page was last updated on 1/19/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.